SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Momenta Pharmaceuticals Inc.
MNTA 52.480.0%Oct 2 5:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: DewDiligence_on_SI who wrote (2527)10/18/2010 2:58:00 AM
From: DewDiligence_on_SI  Read Replies (1) of 3027
 
MNTA ‘ReadMeFirst’ updated:

generic Lovenox has 45% market share;
Canaccord 10/8/10 report has $27 price target;
Wedbush is bullish on MNTA’s Copaxone;
Teva thinks it could lose Copaxone patent case, evidently;
5-year Copaxone data in CIS;
Campath 5-year data from phase-2;
Sanofi’s Teriflunomide cuts MS relapse rate by 31%;
Peptimmune files Citizen Petition against generic Copaxone;
phase-2a data for Regado’s RB006/RB007;
musings on Regado’s threat to MNTA’s M118;
Integrilin whiffs in ‘upstream’ ACS;
generic Arixtra could be approved in 2011;
patent applications re purity of heparin API, Copaxone process, and non-anticoagulant compositions of heparin-based compounds;
M402-related paper in Methods Mol Biol;
FDA label specs for Lovenox dosing by indication;
new version of “What’s New in the Anticoagulant Market?”

siliconinvestor.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News